Publication | Closed Access

Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252

First-line TherapyBreast OncologyMedicineClinical TrialsGynecologyNcctg Study 983252Breast CancerCancer TreatmentOncologyGynecology OncologyEvery-3-week Schedule